# Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma

> **NCT03727880** · PHASE2 · COMPLETED · sponsor: **Lei Zheng** · enrollment: 28 (actual)

## Conditions studied

- Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
- Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Defactinib

## Key facts

- **NCT ID:** NCT03727880
- **Lead sponsor:** Lei Zheng
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-04
- **Primary completion:** 2025-01-15
- **Final completion:** 2025-01-15
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2026-02-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03727880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03727880, "Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03727880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*